JO3370B1 - طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 - Google Patents
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6Info
- Publication number
- JO3370B1 JO3370B1 JOP/2012/0332A JOP20120332A JO3370B1 JO 3370 B1 JO3370 B1 JO 3370B1 JO P20120332 A JOP20120332 A JO P20120332A JO 3370 B1 JO3370 B1 JO 3370B1
- Authority
- JO
- Jordan
- Prior art keywords
- antagonist
- methods
- tumor growth
- antagonizing
- receptor
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000004614 tumor growth Effects 0.000 title abstract 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 4
- 108090001005 Interleukin-6 Proteins 0.000 abstract 3
- 229940122558 EGFR antagonist Drugs 0.000 abstract 1
- 229940123466 ErbB-3 antagonist Drugs 0.000 abstract 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557939P | 2011-11-10 | 2011-11-10 | |
| US201261609968P | 2012-03-13 | 2012-03-13 | |
| US201261613538P | 2012-03-21 | 2012-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3370B1 true JO3370B1 (ar) | 2019-03-13 |
Family
ID=47179020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2012/0332A JO3370B1 (ar) | 2011-11-10 | 2012-11-04 | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20130122003A1 (OSRAM) |
| EP (1) | EP2776468B1 (OSRAM) |
| JP (3) | JP6144689B2 (OSRAM) |
| KR (1) | KR101718748B1 (OSRAM) |
| CN (1) | CN103930443B (OSRAM) |
| AR (1) | AR088671A1 (OSRAM) |
| AU (2) | AU2012335596B2 (OSRAM) |
| BR (1) | BR112014011211A2 (OSRAM) |
| CA (1) | CA2853836C (OSRAM) |
| IL (2) | IL231854A (OSRAM) |
| IN (1) | IN2014CN02923A (OSRAM) |
| JO (1) | JO3370B1 (OSRAM) |
| MX (1) | MX357837B (OSRAM) |
| MY (1) | MY163953A (OSRAM) |
| RU (1) | RU2648150C2 (OSRAM) |
| SG (1) | SG11201401286QA (OSRAM) |
| TW (3) | TW201806620A (OSRAM) |
| UY (1) | UY34444A (OSRAM) |
| WO (1) | WO2013071016A2 (OSRAM) |
| ZA (1) | ZA201402414B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| WO2015000181A1 (zh) * | 2013-07-05 | 2015-01-08 | 华博生物医药技术（上海）有限公司 | 新型重组融合蛋白及其制法和用途 |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016271138A1 (en) * | 2015-05-29 | 2017-12-07 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| CN112203679A (zh) * | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| WO2019178259A2 (en) | 2018-03-14 | 2019-09-19 | Celledit Llc | Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy |
| CN108567981A (zh) * | 2018-07-17 | 2018-09-25 | 漯河医学高等专科学校 | 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用 |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP3908303A4 (en) * | 2019-01-07 | 2023-05-03 | Hunan Siweikang Therapeutics Co. Ltd | MODIFIED IMMUNE CELLS CO-EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND AN IL-6 ANTAGONIST TO REDUCE TOXICITY, AND USES THEREOF IN ADOPTIVE CELL THERAPY |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CA3211803A1 (en) * | 2021-02-27 | 2022-09-01 | Eluminex Biosciences (Suzhou) Limited | Antibody fusion proteins targeting il-6 receptor and angiogenic factors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
| DE122009000019I1 (de) | 1991-04-25 | 2009-07-16 | Chugai Seiyaku K K 5 1 | Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| EP0800829B2 (en) | 1994-12-29 | 2012-07-25 | Chugai Seiyaku Kabushiki Kaisha | Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin |
| US5795695A (en) | 1996-09-30 | 1998-08-18 | Xerox Corporation | Recording and backing sheets containing linear and cross-linked polyester resins |
| HU230159B1 (hu) * | 1999-06-08 | 2015-09-28 | Regeneron Pharmaceuticals, Inc. | VEGF receptor kimérák alkalmazása vaszkuláris permeabilitással jellemzett szembetegség kezelésére |
| US7396664B2 (en) * | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| AU7824900A (en) | 1999-10-07 | 2001-04-23 | Eli Lilly And Company | Compounds and methods for inhibiting mrp1 |
| AU2000279624A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
| US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| ES2393485T3 (es) * | 2003-07-02 | 2012-12-21 | Innate Pharma | Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia |
| AU2004281139B2 (en) | 2003-10-17 | 2011-01-20 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for mesothelioma |
| EP1967209B1 (en) | 2005-11-25 | 2012-06-06 | Keio University | Therapeutic agent for prostate cancer |
| NZ573557A (en) * | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| WO2008154927A1 (en) * | 2007-06-21 | 2008-12-24 | Genmab A/S | Novel methods for treating egfr-associated tumors |
| KR20110112307A (ko) * | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ６의 길항제 |
| US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
-
2012
- 2012-11-04 JO JOP/2012/0332A patent/JO3370B1/ar active
- 2012-11-06 AR ARP120104169A patent/AR088671A1/es not_active Application Discontinuation
- 2012-11-09 KR KR1020147012146A patent/KR101718748B1/ko active Active
- 2012-11-09 CA CA2853836A patent/CA2853836C/en active Active
- 2012-11-09 UY UY0001034444A patent/UY34444A/es unknown
- 2012-11-09 CN CN201280055109.4A patent/CN103930443B/zh active Active
- 2012-11-09 EP EP12787338.8A patent/EP2776468B1/en active Active
- 2012-11-09 US US13/672,923 patent/US20130122003A1/en not_active Abandoned
- 2012-11-09 MX MX2014004886A patent/MX357837B/es active IP Right Grant
- 2012-11-09 JP JP2014541298A patent/JP6144689B2/ja active Active
- 2012-11-09 TW TW106138384A patent/TW201806620A/zh unknown
- 2012-11-09 AU AU2012335596A patent/AU2012335596B2/en active Active
- 2012-11-09 SG SG11201401286QA patent/SG11201401286QA/en unknown
- 2012-11-09 WO PCT/US2012/064311 patent/WO2013071016A2/en not_active Ceased
- 2012-11-09 TW TW105142150A patent/TW201716776A/zh unknown
- 2012-11-09 MY MYPI2014000968A patent/MY163953A/en unknown
- 2012-11-09 TW TW101141702A patent/TWI604852B/zh active
- 2012-11-09 RU RU2014118739A patent/RU2648150C2/ru active
- 2012-11-09 BR BR112014011211A patent/BR112014011211A2/pt not_active Application Discontinuation
-
2014
- 2014-04-01 IL IL231854A patent/IL231854A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02414A patent/ZA201402414B/en unknown
- 2014-04-17 IN IN2923CHN2014 patent/IN2014CN02923A/en unknown
- 2014-07-11 US US14/329,565 patent/US9409990B2/en active Active
-
2016
- 2016-07-07 US US15/204,639 patent/US20170022279A1/en not_active Abandoned
- 2016-10-30 IL IL248620A patent/IL248620A0/en unknown
-
2017
- 2017-01-06 JP JP2017000818A patent/JP6283754B2/ja active Active
-
2018
- 2018-01-26 JP JP2018011135A patent/JP2018083841A/ja not_active Withdrawn
- 2018-05-24 AU AU2018203666A patent/AU2018203666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3370B1 (ar) | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 | |
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| MX368068B (es) | Antagonista de il-4r para usarse para tratar la poliposis nasal. | |
| EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
| EP4374919A3 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| EA201490369A1 (ru) | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek | |
| MX2018005340A (es) | Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos. | |
| IN2014DN09098A (OSRAM) | ||
| UA107827C2 (xx) | Антитіло до cd40 | |
| EP4219552A3 (en) | Il-11r binding proteins and uses thereof | |
| WO2012071561A3 (en) | Anti-il-6 antibodies for the treatment of anemia | |
| SG10201807042YA (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same | |
| MX2013012572A (es) | Anticuerpos anti-cd40 y metodos de uso. | |
| MX2019003942A (es) | Anticuerpos anti-pd-l1 y antagonistas de vegf y su uso en el tratamiento del cancer. | |
| WO2011154139A3 (en) | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment | |
| MX365242B (es) | El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. | |
| AU2014306956B2 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| MX360774B (es) | Antagonistas de progesterona. | |
| PH12015500751A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4 | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| BR112014014824A2 (pt) | anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos | |
| MX2016007947A (es) | Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas. |